DHR vs MRK: Which Is the Better Buy?
Side-by-side comparison of Danaher Corporation and Merck & Co., Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-10.
Danaher Corporation · Healthcare
$195.98
+7.9% upside to fair value
Grade B
High Quality
VS
Merck & Co., Inc. · Healthcare
$113.87
-12.1% upside to fair value
Grade D
High Quality
QuantHub Verdict
DHR has more upside to fair value
(+7.9%).
MRK trades at a lower forward P/E
(32.0x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DHR |
MRK |
| Current Price |
$195.98 |
$113.87 |
| Fair Value Estimate |
$211.54 |
$100.14 |
| Upside to Fair Value |
+7.9%
|
-12.1%
|
| Market Cap |
$138.7B |
$281.2B |
| Forward P/E |
37.8x
|
32.0x
|
| EV / EBITDA |
22.8x
|
17.3x
|
| Price / Sales |
5.6x
|
4.3x
|
| Price / FCF |
26.2x
|
19.9x
|
| Revenue Growth YoY |
+3.7%
|
+4.3%
|
| Gross Margin |
60.7%
|
75.9%
|
| Operating Margin |
21.0%
|
27.6%
|
| Return on Equity |
7.1%
|
17.9%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.81%
|
5.02%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Danaher Corporation operates in the healthcare sector, specifically in medical diagnostics and research, delivering high-quality products with a durable competitive moat supported by strong margins and consistent earnings growth. The company trades at a trailing and forward P/E of 37.76, which is relatively high but justified by its stable revenue growth of 3.7% and earnings growth of 7.9% in the…
Merck & Co., Inc. is a leading global healthcare company specializing in pharmaceuticals, vaccines, and animal health products. Its business quality is high, supported by a durable competitive moat anchored in the dominant global position of Keytruda in PD-1/PD-L1 oncology, a strong vaccines portfolio including Gardasil, and scale in R&D and manufacturing. The company benefits from a seasoned lea…
Accumulation Zones
| Metric |
DHR |
MRK |
| Zone Low |
$158.66 |
$75.11 |
| Zone High |
$179.81 |
$85.12 |
| In Buy Zone? |
No
|
No
|